CC BY
42
Практична медицина I Practical Medicine
БШЬ.
СуГЛОБИ. JOINTS. I ХРЕБЕТ SPINE I
УДК616.72-002:616.517]-08(083.13)"2018" DOI: 10.22141/2224-1507.9.1.2019.163058
I.Yu. Golovach1, Ye.D. Yehudina2
1Clinical Hospital "Feofaniya" of the Agency of State Affairs, Kyiv, Ukraine
2State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Dnipro, Ukraine
Recent recommendations on psoriatic arthritis treatment in accordance with 2018 American College of Rheumatology and National Psoriasis
Foundation guidelines
For cite: Bol', sustavy, pozvonocnik. 2019;9(1):46-58. doi: 10.22141/2224-1507.9.1.2019.163058
Abstract. Psoriatic arthritis (PsA) is a chronic inflammatory skeletal and muscular disease associated with psoriasis, which usually manifests itself in the peripheral arthritis, dactylitis, enthesitis and/or spondylitis. Early identification and diagnosis of PsA, as well as early start of therapy is important for improving the long-term outcomes of the disease. Clinical picture of PsA is heterogeneous, and doctors often face problems while determining treatment strategies. The purpose of our review was to discuss and interpret 2018 American College of Rheumatologists (ACR) and National Psoriasis Foundation (NPF) guidelines for active PSA treatment in adults using pharmacological and non-pharmacological methods. These recommendations may help both clinicians and patients to make their best decisions about disease management. The presence or absence of comorbid conditions such as inflammatory bowel disease, uveitis, diabetes or serious infections, as well as knowledge of medical history are factors enabling choice of an optimal therapy for a particular patient at a given time using a customized treatment approach. ACR/NPF guidelines for active PsA treatment recommend tumor necrosis factor inhibitors rather than small molecule oral drugs as a first line therapy, precisely because these biological agents prevent progression of the disease and joint damage. Early and aggressive therapy is emphasized in patients with a newly diagnosed PsA.
Keywords: psoriatic arthritis; psoriasis; activity of the process; recommendations; treatment; management; tumor necrosis factor inhibitors; interleukin-17 inhibitors; interleukin-12/23 inhibitors; methotrexate; treat-to-target
Psoriatic arthritis (PsA) is a chronic inflammatory psoriasis-associated disease affecting both skeleton and muscles. PsA usually manifests itself as a peripheral arthritis, dactylitis, enthesitis and/or spondylitis. Moreover, 80-90% of PsA patients suffer from nail-affecting conditions, such as localized pockmarks and onycholysis [1]. PsA frequency is about 6 cases per 100 thousand annually, while its prevalence is 1-2 cases per 1000 in overall population [2]. Annual PsA incidence in patients with psoriasis is 2.7% [3], while the registered PsA prevalence in patients with psoriasis varies from 6 to 41% [2]. PsA incidence is not sex-specific. PsA is associated with a negative life quality effect [4] and high medical costs [5]. Disease is very active and
associates itself with a progressive destructive arthritis, functional insufficiency, disability, co-morbidity and high mortality [6].
Skin lesions are usually the first to occur, while arthritis develops itself over a period of time. However, in some patients, skin lesions and joint conditions reveal themselves at the same time, and in 10-15 % of cases arthritis is the first clinical sign [3]. It is these PsA cases that are most difficult to diagnose at an early stage.
Clinical forms
Clinical varieties of peripheral arthritis range from an asymmetric oligoarthritis (affecting <4 joints) to a symmetric polyarthritis (affecting >5 joints). Affected
© «Бшь. Суглоби. Хребет» / «Боль. Суставы. Позвоночник» / «Pain. Joints. Spine» (<ЯоГ, sustavy, pozvonocnik»), 2019 © Видавець Заславський О.Ю. / Издатель Заславский А.Ю. / Publisher Zaslavsky O.Yu., 2019
Для кореспонденци: Головач 1рина Юрпвна, доктор медичних наук, професор, MBA, заслужений лтар Укра'ши, ^вник центру ревматологи, КлЫчна л^арня «Феофани» Державного управлшня справами, вул. Академк Заболотного, 21, м. КиТв, 03680, УкраТна; e-mail: golovachirina@gmail.com
For correspondence: Iryna Golovach, MD, PhD, Professor, MBA, Honored Doctor of Ukraine, Head of the Center of rheumatology, Clinical Hospital "Feofaniya" of the Agency of State Affairs, Academic Zabolotny st., 21, Kyiv, 03680, Ukraine, e-mail: golovachirina@gmail.com
distal phalangeal joints (DPJs) are a pathognomonic sign as sometimes they are the only ones bearing PsA marks. Axial spondylarthritis usually occurs together with a peripheral arthritis. Some patients may have a quickly progressing and debilitating PsA; this PsA is also called mutilating.
Table 1 presents PsA clinical forms.
Diagnostic criteria
PsA is diagnosed according to CASPAR (Classification ^iterta for Psoriatic Arthritis) established by W. Taylor et al. in 2006 [7]. These criteria have a high sensitivity and specificity both at an early and advanced PsA stage. These criteria enable diagnostics irrespective of a positive RA and absence of psoriasis, if typical PsA signs are present.
According to CASPAR, patients should have inflammatory joint conditions (arthritis, spondylitis or enthesitis) and >3 points out of those presented in Table 2.
PsA clinical picture is rather heterogeneous, which is why physicians rarely reach consensus as to the
Table 1. PsA
treatment options. We aim to review the American College of Rheumatologists (ACR) Guidance of 2018 on how to treat an active PsA in adults with pharmacological and non-pharmacological methods. Those recommendations may help both clinicians and patients to make optimum decisions about PsA management.
Determination of PsA activity and severity; effectiveness of treatment
Treatment guidance mainly concerns an active PsA form. While determining PsA activity, we should take into account at least one of the following symptoms: arthritis, dactylitis, enthesitis, axial skeleton damage, active skin and/or nail lesions, extra-articulatory manifestations such as uveitis or inflammatory bowel disease (IBD). It is also essential to pay attention to the following inflammation markers: C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), and joint and bone imaging [8].
To evaluate the effectiveness of treatment, randomized controlled studies primarily use ACR criteria [9]:
PsA clinical form Primary characteristics
Distal form Primarily affects hand and foot DPJs. Classic isolated hand and/or foot DPJs is observed in 5 % of cases. Affected DPJs often occur in other clinical forms as well.
Asymmetric mono- and oligoarthritis Typical of most PSA patients (up to 70 %). Primarily affects knee, radius, ankle and elbow joints; also hand and foot proximal phalangeal joints (PPJs), metacarpophalangeal and metatarsophalangeal joints. The total number of affected joints is < 4.
Rheumatoid-resembling symmetric polyarthritis Occurs in 15-20% PSA patients. Characterized by pairs of joints being affected, as in RA. Often manifests itself as an asymmetric polyarthritis of > 5 joints
Psoriatic spondylitis (isolated or in connection with a peripheral arthritis) Characterized by a generalized spinal (spondylitis), sacroiliac inflammation (sacroiliitis) similar to ankylosing [rheumatoid] spondylitis. However, most often sacroiliitis is unilateral; 50 % of cases have it combined with a peripheral arthritis. Isolated spondylitis is rare (2-4%)
Mutilating arthritis A rare clinical form observed in 5 % of cases. Characterized by a wide-rangingjoint surface resorption (osteolysis), shortening of fingers and/or toes, 'telescopic' deformation; multidirectional subluxations (windblown fingers). However localized (restricted) osteolysis may develop in all clinical forms
Notes: DPJs - distal phalangeal joints; PPJs - proximal phalangeal joints; PsA - psoriatic arthritis; RA - rheumatoid arthritis.
Table 2. CASPAR
Signs Points
1. Psoriasis:
At the examination 2
Patient's history 1
Family history 1
2. Psoriatic nail dystrophy (pinpoint marks, onycholysis, hyperkeratosis) 1
3. Negative RF (but for latex test) 1
4. Dactylitis:
finger swollen at the examination 1
Patient's history 1
5. X-ray reveals abarticular bone proliferation similar to boundary growth (but for osteophytes) of hand and foot 1
1. Number of painful joints (NPJ) (out of 68);
2. Number of swollen joints (NSJ) (out of 66);
3. General evaluation of disease activity by the physician using a visual analogue scale (VAS), mm;
4. General evaluation of disease activity by the patient using a visual analogue scale (VAS), mm;
5. Joint pain evaluation by the patient using a visual analogue scale (VAS), mm;
6. Evaluation of functional ability loss (Health Assessment Questionnaire, HAQ);
7. Acute stage indices (CRP, ESR).
ACR20 criterion shows a 20 %-improvement of at least 5 out of 7 above-mentioned parameters (improvement of the first two is a must) compared to the initial level, i.e. a satisfactory therapeutic effect; ACR50 criterion shows a 50 %-improvement, i.e. a good therapeutic effect; ACR70 criterion shows a 70 %-improvement, i.e. an exemplary therapeutic effect. If the EULAR criteria of effectiveness are used in every day medical practice, then ACR criteria are primarily reserved for the research papers and clinical studies [10]. DAS index helps determine the degree of disease activity while its dynamics with treatment gives physicians an idea as to the treatment effectiveness rate. At the same time, ACR criteria could only prove or disprove treatment-based positive dynamics [11].
Patients and physicians should determine PsA and psoriasis activity in every special case, taking into account not only a degree of activity at a specific point in time but presence or absence of negative prognosticating factors in the long term. If the disease is found to be severe, it should have at least one of the negative prognosticating factors:
- Erosive process;
- Dactylitis;
- Increased levels of PsA-related inflammatory markers (CRP, ESR);
- Irrevocable joint damage;
- Function-compromising joint deformations;
- High disease activity provoking serious life quality issues (for instance, active inflammation at numerous sites, including dactylitis, enthesitis, restriction of several joint group functions);
Table 3. Criteria of sever
- Long-term impairment (for instance, vision loss);
- Quick progress of the disease;
- Active psoriasis infiltration at numerous sites.
As nowadays there are no agreed psoriasis severity markers, it should be determined by the physician and patient in every special case. In clinical studies, psoriasis severity and proliferation (area) index (PASI) >12 is combined with the damaged body surface area (BSA) >10 [12]. Examples of PsA and psoriasis severity are presented in Table 3. Finally, as the National Psoriasis Foundation (NPF) and the American Academy of Dermatology (AAD) are both elaborating the psoriasis treatment guidance, it's not included on the recent ACR PsA guidance.
From guideline to practice
The Guidelines of ACR/NFP'2018 were developed in order to help the healthcare staff to choose the best therapeutic option for PsA patients. Presence or absence of co-morbidities such as uveitis, inflammatory bowel disease (IBD), diabetes and severe infections, as well as awareness of medication history influence the PsA management strategy. In PsA case, there should be an objective examination of peripheral joints (for instance, to diagnose dactylitis), spine, skin and nails, evaluation of existing enthesites. Physicians and patients should take into account existing co-morbidities and patient's functional state at the time of decision-making as to the optimal therapy.
Early PsA identification and diagnostics as well as the early therapeutic intervention are of extreme importance for improving long-term disease outcomes [13]. Both pharmacological and non-pharmacological treatment (Fig. 1) may reduce PsA symptoms and signs and bring remission [14]. Nowadays clinicians and patients may choose out of a great range of pharmacological cures, among them symptomatic (non-steroid anti-inflammatory drugs (NSAIDs), systemic glucocorticoids (GCs), local (intra-articular) GC injections) and immune-modulating, among them oral small-molecule drugs (OSMDs), tumor necrosis inhibitor drugs (TNF inhibitors), interleukin inhibitors (IL inhibitors), immunoglobulin, janus kinase inhibitors (JK inhibitors).
>sA and severe psoriasis
Severe psoriatic arthritis Severe psoriasis
• Erosive disease • Increased levels of PsA-related inflammatory markers (CRP ESR) • Irrevocable joint damage compromising their function • Highly active disease affecting life quality • Active inflammation at numerous sites, including dactylitis, enthesitis • Restricted function at several sites • Quickly progressing disease • PASI > 12 • BSA > 5-10% • Significant lesions of isolated sites (face, hands, feet, nails, folds, scalp) affecting function and life quality • Deterioration of physical or mental state results in diagnosing moderate or severe psoriasis despite the small damage area
Notes: PASI - Psoriasis Area and Severity Index; BSA - Body Surface Area Composite Tool for Assessing Psoriasis; CRP - C-reactive protein; PsA - psoriatic arthritis; ESR - erythrocyte sedimentation rate.
ACR/NFP'2018 Guidelines on PsA treatment
Active PsA in patients not receiving treatment (Fig. 2) [15-28].
For the treatment of PsA patients who didn't receive any previous therapy (naïve), biological agents and TNF inhibitors in particular are considered the line of first defense. Basic drugs, such as Methotrexate (MTX), Sulfasalazine (SSZ), Cyclosporine, Lefluno-mide, might be used instead of TNF inhibitors in case of a non-severe PsA form and absence of severe psoriasis (as Table 3 puts it, the degree of severity is decided upon by the physician and patient), for those patients who prefer to take drugs per os rather that by parenteral way, or have TNF inhibitor contraindications, such as congestive heart failure, previous severe or recurring infections, demyelinating diseases, casting doubt on the biological therapy benefit.
To treat active PsA in patients who didn't receive any PsA-related therapy, it's necessary to choose TNF inhibitors or basic therapy and small-molecule drugs over IL inhibitors — 17 or IL inhibitors — 12/23. The latter may replace TNF inhibitors in patients with a severe psoriasis and TNF inhibitor contraindications. Between IL inhibitors — 17 and IL inhibitors — 12/23, the former are more effective while the latter may serve as protectors against an inflammatory bowel disease (IBD) and/or severe psoriasis and/or severe PsA or in case a patient wishes the drug to be administered rarely.
If the choice is between NSAIDs and MTX, it's suggested that MTX works better for active PsA or psoriasis patients. NSAIDs may be used instead MTX after a review of all possible contraindications and evaluation of side effects in patients without a severe PsA or psoriasis, and those with no risk of NSAID-associated cardio- and nephrotoxic effects.
Active PsA despite basic drugs administered per os (Fig. 3).
Some patients retain an active PsA despite taking basic drugs (Methotrexate (MTX), Sulfasalazine (SSZ), Cyclosporine, Leflunomide). In this case the healthcare providers should suggest TNF inhibitors, IL inhibitors — 17 or IL inhibitors — 12/23 rather than another basic drug. However, those patients who prefer to take drugs per os or have no signs of a severe PsA or psoriasis may still try another basic therapy option rather than TNF inhibitors, IL inhibitors — 17 or IL inhibitors — 12/23. It is worthy of note that another basic therapy option (Methotrexate (MTX), Sul-fasalazine (SSZ), Cyclosporine, Leflunomide) may be prescribed in case of biological drug contraindications.
As it was previously mentioned, among the biological drugs TNF inhibitors have an edge over IL inhibitors — 17 or IL inhibitors — 12/23, Abataceptum or Tofacitinibum. While choosing among those, keep in mind that IL inhibitors — 17 are more effective than
IL inhibitors — 12/23, Abataceptum or Tofacitinibum while IL inhibitors — 12/23 — more effective than Abataceptum or Tofacitinibum [31]. Tofacitinibum may be substituted for TNF inhibitors in those patients who prefer to take drugs per os or have no signs of a severe psoriasis [32].
Switching to a new basic therapy option is a better strategy than adding a new one belonging to the same group (but for Apremilast). It is suggested only if a patient gave a partial response to the current per os basic therapy. In this case, adding Apremilast to the current basic therapy is more effective than administering Apremilast as a mono-therapy. Most studies of Apre-milast's effectiveness concern combined therapies with Methotrexate (MTX), Sulfasalazine (SSZ), Leflunomide [33]. Mono-therapy is preferred to a combined therapy only if a patient has significant side effects associated with the current basic medication (Methotrexate (MTX), Sulfasalazine (SSZ), Cyclosporine, Leflunomide).
It is interesting that a biological mono-therapy turns out more effective than a combined one, if MTX is used together with biological agents. While switching to a biological mono-therapy, one should stop taking basic medication if it's a justified option chosen by both patient and healthcare provider [34]. Biological agent in combination with MTX replaces mono-therapy if a patient has a severe psoriasis, makes a partial response to a current MTX therapy or has a concomitant uveitis (this condition is MTX-treatable). Patients getting TNF inhibitors, especially Infliximab or Adalimumab, are recommended the combined therapy in order to delay or prevent antibody production.
Non-pharmacological treatment Physiotherapy, occupational therapy, smoking cessation, weight loss, massage, physical exercise
Symptomatic therapy Non-steroid anti-inflammatory drugs, glucocorticoids, local glucocorticoid injections
Basic therapy and small molecules Methotrexate (MTX), Sulfasalazine (SSZ), Cyclosporine, Leflunomide, Apremilast
TNF inhibitors Etanercept, Infliximab, Adalimumab, Golimumab, Certolizumab
IL inhibitors - 12/23 Ustekinumab
IL inhibitors - 17 Secukinumab, Ixekizumab, Brodalumab
CTLA4-Ig Abataceptum
Janus kinase inhibitors Tofacitinibum
Fig. 1. PsA pharmacological and non-pharmacological treatment. Pharmacological methods are highlighted in blue and involve a basic therapy and small-molecule drugs, TNF inhibitors, interleukin-17 inhibitors (IL inhibitors - 17), interleukin-12/23 inhibitors (IL inhibitors - 12/23), CTLA4-immunoglobulin and Janus kinase inhibitor. Despite numerous
non-pharmacological methods, only 6 are considered the most effective: physiotherapy, occupational therapy, smoking cessation, weight loss, massage, physical exercise.
Active PsA despite TNF inhibitors administered both as a mono- and combined therapy (Fig. 4).
Patients who retain PsA despite being treated by TNF inhibitor mono-therapy should be switched to a different TNF inhibitor rather than to IL inhibitors — 17 or IL inhibitors — 12/23, Abataceptum or Tofaci-tinibum. It is not advisable to add MTX to a current TNF inhibitor. In case of a complete absence of clinical effect from a previous TNF inhibitor or its significant side effects, IL inhibitors — 17 or IL inhibitors — 12/23, Abataceptum or Tofacitinibum should be prescribed instead of a different TNF inhibitor mono-therapy [35]. Abataceptum may be used if there is a serious or recurring infection but no severe psoriasis, according to the data on infection reduction when patients with RA were taking Abataceptum rather than TNF inhibitor [36]. If a patient prefers a per os administration, To-facitinibum is a good alternative.
If PsA remains active despite TNF inhibitors, the second line of defense may involve IL inhibitors — 17 rather than IL inhibitors — 12/23, Abataceptum or To-facitinibum. Among the latter group of drugs, IL inhibitors — 12/23 are more effective than Abataceptum or Tofacitinibum. IL inhibitors — 12/23 are used instead of IL inhibitors — 17 when a patient has an inflammatory bowel disease (IBD) or prefers a rare drug administration. Abataceptum is an alternative to IL inhibitors — 17 and IL inhibitors — 12/23 when there is a recurring serious infection. Tofacitinibum might
replace IL inhibitors — 17 and IL inhibitors — 12/23 for patients who prefer per os administration or have a history of recurring serious Candida infection [36]. For every biological agent (TNF inhibitor, IL inhibitors — 17 and IL inhibitors — 12/23) mono-therapy seems a better option than a MTX-combined one. MTX combined with a biological agent is used instead of a biological mono-therapy when a patient has a severe psoriasis, partial response to the current MTX therapy, uveitis. Biological TNF inhibitor used should be either Infliximab or Adalimumab (to prevent immunogenic response) [38].
In case when even after a combined therapy with TNF inhibitor and MTX PsA still remains active, a switch should be for another TNF inhibitor and MTX, rather than for a TNF inhibitor mono-therapy. Continued administration of MTX together with TNF inhibitor seems efficacious because when combined with MTX biological agents demonstrate a consistent effect [39]. Mono-therapy with a different TNF inhibitor may be used is a patient suffers from MTX-associated side effects, wants to restrict the amount of medication or considers MTX therapy a burden. Combined therapy of IL inhibitors — 17 or IL inhibitors — 12/23 together with MTX is not advisable as a mono-therapy provides a better effect. However, if IL inhibitors — 17 or IL inhibitors — 12/23 elicited a partial response or a patient has a concomitant uveitis, these medications may be combined with MTX [40].
Fig. 2. Active PsA in the untreated PsA patients (adapted from [19]). Notes: TNF inhibitors - tumor necrosis inhibitor drugs; IL inhibitors - 17 - interleukin inhibitors- 17; IL inhibitors - 12/23 - interleukin inhibitors- 12/23; MTX - Methotrexate; PsA - psoriatic arthritis. Review the alternative drugs: IL inhibitors - 17 or IL inhibitors - 12/23 might be used instead of TNF biological inhibitors in severe psoriatic patients or under TNF inhibitor contraindications; basic drugs per os, IL inhibitors - 17 or IL inhibitors - 12/23 under TNF inhibitor contraindications; basic therapy and small-molecule drugs in case of patient's reluctance to start biological drugs and preference for per os administration, IL inhibitors - 12/23 in case a patient wishes the drug to be administered rarely. Review the alternative drugs: IL inhibitors - 17 or IL inhibitors - 12/23 might be used instead of basic therapy per os in severe psoriatic and PsA patients; IL inhibitors - 12/23 in case of a concomitant active inflammatory bowel disease (IBD) or in case a patient wishes the drug to be administered rarely. NSAIDs may replace MTX in patients with an inactive PsA following the cardiac and renal-associated risks. IL inhibitors - 12/23 may be used in case of a concomitant active inflammatory bowel disease (IBD) or in case a patient wishes the drug to be administered rarely.
Active PsA despite IL inhibitor - 17 mono-therapy (Fig. 5)
If PsA remains active despite IL inhibitor — 17 mono-therapy, TNF inhibitor is suggested; however, it should be unaccompanied by IL inhibitors — 12/23 or MTX. Prescription of a different IL inhibitor — 17 is also discouraged [40].
Switch to IL inhibitors — 12/23 is a more effective option than adding MTX to IL inhibitor — 17 or using a different IL inhibitor — 17. If a patient has a severe psoriasis and contraindications prevent TNF inhibitor use, IL inhibitor — 17 should be replaced by IL inhibitors - 12/23 [41].
Another biological IL inhibitor — 17 might be used instead of switching to TNF inhibitor or IL inhibitors — 12/23 if a patient has a secondary ineffectiveness due to a modern biological treatment, severe psoriasis or TNF inhibitor contraindications [42]. MTX may be added to the current IL inhibitor — 17 therapy instead of switching to TNF inhibitor or IL inhibitors — 12/23 if a patient had a partial response to IL inhibitor — 17 therapy in the past [42].
Active PsA despite IL inhibitor - 12/23 mono-therapy (Fig. 5).
If PsA remains active despite IL inhibitor — 12/23 mono-therapy, TNF inhibitor, MTX addition or switching to IL inhibitor — 17 are suggested. Switching to IL inhibitor — 17 is a better strategy than adding MTX to a current therapy [43]. Treatment may include IL inhibitor — 17 rather than TNF inhibitor if a patient has a severe psoriasis or TNF inhibitor contraindications [42]. MTX may be added to IL inhibitor — 12/23
instead of a switch to TNF inhibitor or IL inhibitor — 17 if a patient shows a partial response to this therapy; it may also be added instead of a switch to TNF inhibitor if there are TNF inhibitor contraindications [20].
Т2Т (Treat-to-target) therapy
If PsA is active, a well-known T2T (Treat-to-target) therapy is recommended. It presupposes the treatment until the cure is achieved. Dismissal of this strategy occurs when the healthcare providers have certain concerns as to the adverse or side effect intensification or onset, treatment costs or biological agents being incapable to control the current therapy.
Active PsA with spondylitis/axial damage despite NSAIDs
Basic drugs administered per os unfortunately are ineffective for axial PsA [44]. Patients, who retain active axial PsA despite NSAID treatment, should switch to TNF inhibitors, at the further stage — to IL inhibitor — 17, later — to IL inhibitor — 12/23. IL inhibitor — 17 is used instead of TNF inhibitors in case of a severe psoriasis or existing TNF inhibitor contraindications. IL inhibitor — 12/23 seems to be the least effective in this clinical situation, as the results of three randomized studies of Ustekinumab show lack of primary and secondary cut-off points achieved [45-47].
Active PsA with prevailing enthesitis in the untreated patients or patients who received basic drugs per os and did not show any response
The untreated patients with enthesites may use TNF inhibitor biological agents as medications of the first
Active PsA despite basic therapy
Switching to TNF inhibitors1 rather than another basic medication2, IL inhibitors - 17 or IL inhibitors - 12/23, Abataceptum or Tofacitinibum3. Review the alternative drugs under special circumstances5 Switching to IL inhibitors - 171, rather than another basic medication per os2, IL inhibitors - 12/23, Abataceptum or Tofacitinibum4. Review the alternative drugs under special circumstances6 Switching to IL inhibitors - 12/231, rather than another basic medication per os2, Abataceptum or Tofacitinibum4. Review the alternative drugs under special circumstances7
Fig. 3. Active PsA in patients treated by the per os basic therapy (adapted from [19]). Notes: TNF inhibitors - tumor necrosis inhibitor drugs; IL inhibitors - 17 - interleukin inhibitors- 17; IL inhibitors - 12/23 - interleukin inhibitors- 12/23; PsA - psoriatic arthritis. Mono-therapy by the biological drugs is considered more effective than a combined one with MTX and biological drug. Apremilast is more effective when added to a combined therapy than on its own. Switch is recommended to another basic drug (but for Apremilast) than to a drug from a different group. If a patient has an active PsA despite TNF inhibitors. If a patient has an active PsA despite IL inhibitors - 17 or IL inhibitors - 12/23. Alternative medicine may be suggested if a patient has a severe psoriasis (IL inhibitors - 17 or IL inhibitors - 12/23), TNF inhibitor contraindications. Alternative medicine may be suggested if a patient has an inflammatory bowel disease (IBD) (IL inhibitors - 12/23), recurring or serious infections (Abataceptum); recurring Candidosis (Tofacitinibum); patient wishes the drug to be administered rarely (IL inhibitors - 12/23); with no severe psoriasis to be replaced with basic per os medications. Alternative medicine may be suggested if a patient does not have a severe PsA or psoriasis (basic per os medications); has recurring or serious infections (Abataceptum); prefers per os administration (basic per os medications, Tofacitinibum).
line of defense [48]. Patients with active PsA who suffer from enthesitis despite taking basic drugs per os (the latter were prescribed for other PsA manifestations and other clinical situations) are recommended to switch to TNF inhibitors, IL inhibitor — 17 or IL inhibitor — 12/23 rather than to other medications of the same group. Usually TNF inhibitors are the line of first defense, IL inhibitor — 17 - the line of second defense, IL inhibitor - 12/23 - the line of third defense [48]. If a patient has a severe psoriasis and TNF inhibitor contraindications, he/she should start IL inhibitor -17. If he/she prefers a rarer drug administration, has an inflammatory bowel disease (IBD), the best option is IL inhibitor — 12/23. Apremilast may replace TNF inhibitors in case a patient prefers per os drug administration or TNF inhibitor contraindications [33]. Per os NSAID's efficacy in case of concomitant enthesites prevails over that of basic per os drugs. They may be prescribed is a patient has no cardiovascular conditions, ulcers, kidney diseases (or failures) or severe
psoriasis, PsA. Tofacitinibum has an edge over Apremilast in case of PsA with prevailing enthesitis [37]. The latter, however, is advisable for patients with recurring infections.
Active PsA with an active concomitant inflammatory bowel disease (IBD)
To treat the previously untreated patients with an active PsA with an active concomitant inflammatory bowel disease (IBD), healthcare providers opt for TNF inhibitors (but for Etanercept which is a biological molecule of soluble receptors and thus ineffective in this clinical situation). Basic per os drugs may be used by the patients with no severe PsA preferring per os drug administration or having TNF inhibitor contraindications [49].
If an active PsA is diagnosed along with an active inflammatory bowel disease (IBD) despite being treated with basic drugs, TNF inhibitor or IL inhibitor — 12/23 monoclonal antibodies are a medication of choice.
Switching to a different TNF inhibitor1 rather than IL inhibitors - 17 or IL inhibitors - 12/23, Abataceptum, Tofacitinibum, or added MTX. Review the alternative drugs under special circumstances2
Switching to IL inhibitors - 171 rather than IL inhibitors -12/23, Abataceptum, Tofacitinibum. Review the alternative drugs under special circumstances3
Switching to IL inhibitors - 12/231 rather than Abataceptum, Tofacitinibum4.
Review the alternative drugs under special circumstances4
Switching to a different TNF inhibitor + MTX rather than mono-therapy with a different TNF inhibitor. Review the alternative drugs under special circumstances5
Switching to IL inhibitor - 17 mono-therapy rather than a combined therapy of IL inhibitor - 17 + MTX.
Review the alternative drugs under special circumstances6
Switching to IL inhibitor - 12/23 mono-therapy rather than a combined therapy of IL inhibitor -12/23 + MTX.
Review the alternative drugs under special circumstances6
Fig 4. Active PsA despite TNF inhibitors as a mono- or combined therapy (adapted from [19]). Notes: TNF inhibitors - tumor necrosis inhibitor drugs; IL inhibitors - 17 - interleukin inhibitors- 17; IL inhibitors - 12/23 - interleukin inhibitors- 12/23; PsA - psoriatic arthritis; MTX - Methotrexate; oral small-molecule drugs (OSMDs). Biological drug mono-therapy is considered more effective than a combined one with MTX. If the patient did not show any response to TNF inhibitors, there might be alternative suggestions (IL inhibitors - 17 or IL inhibitors - 12/23, Abataceptum or Tofacitinibum); if there are serious TNF inhibitor-associated side effects (IL inhibitors - 17 or IL inhibitors - 12/23, Abataceptum or Tofacitinibum); if a patient showed a partial response to TNF inhibitors, especially immunogenic (add MTX); if a patient prefers per os administration (Tofacitinibum); if a patient has a severe psoriasis (IL inhibitors - 17); if a patient prefers a rare drug administration (IL inhibitors - 12/23). Alternative options should be considered in case of a concomitant inflammatory bowel disease (IBD) (IL inhibitors - 12/23, Tofacitinibum); preference for an intravenous administration (Abataceptum); serious or recurring infections (Abataceptum); preference for per os administration (Tofacitinibum); history of Candidosis (Tofacitinibum); preference for a rare drug administration (IL inhibitors - 12/23). Alternative options should be considered if a patient prefers an intravenous administration (Abataceptum); has serious or recurring infections (Abataceptum); prefers per os administration (Tofacitinibum). TNF inhibitor mono-therapy is to be suggested if a patient develops serious MTX-associated side effects or wants to restrict the amount of medication. IL inhibitors - 17+MTX combined therapy is an option if a patient has a partial response to therapy or uveitis. IL inhibitors - 12/23+MTX combined therapy is an option if a patient has a partial response to therapy or uveitis.
Moreover, TNF inhibitor-a monoclonal antibodies should be taken over soluble TNF inhibitor-a receptor (Etanercept). TNF inhibitor-a monoclonal antibodies are considered more effective than IL inhibitor — 12/23. The latter may be used in case of TNF inhibitor contraindications or a preference for a rarer drug administration [50].
Active PsA with concomitant diseases
Active PsA in diabetes patients who don't receive basic per os therapy or biological agents. Patients with an active PsA and concomitant diabetes who don't receive basic per os therapy (Methotrexate (MTX), Sulfasalazine (SSZ), Cyclosporine, Leflunomide) or biological agents are recommended to start with basic drugs (except for MTX) rather than with biological agents. MTX exclusion is explained by the concerns about fatty hepatosis prevalence, MTX and bioagents' increased hepatotoxicity for this group of patients [51, 52]. TNF inhibitor may be substituted for basic per os therapy in case of a severe PsA or psoriasis, well-controlled diabetes with a potentially reduced infection risk).
Active PsA in patients with severe infections who don't receive basic per os therapy or biological agents. Patients with an active PsA and severe infections who don't receive basic per os therapy or biological agents should first address basic drugs rather than TNF inhibitors as
severe infections are an absolute contraindication for the latter administration. It's possible to consider such biological agents as IL inhibitor — 17 or IL inhibitor — 12/23.
Inoculation with live and inactivated vaccines for patients with an active PsA treated with bioagents
According to the Centers for Disease Control and Prevention (CDC), it is suggested to start treatment with biological agents without delay, and get patients inoculated with killed or inactivated vaccines based on the patient's age, sex and inoculation history. If the live (unattenuated) vaccines are required, biological therapy of patients with an active PsA should be delayed. In case PsA manifestations are significant and the delay seems undesirable, the healthcare provider may consider starting the treatment and injecting live (unattenuated) vaccines at the same time.
Recommendations on non-pharmacological interventions in patients with an active PsA irrespective of pharmacological treatment
Patients with an active PsA may perform certain physical exercises or their combinations; undergo physiotherapy, occupational therapy, massage and
Fig. 5. Active PsA despite IL inhibitor - 17, IL inhibitor - 12/23 mono-therapy (adapted from [19]). Notes: TNF inhibitors - tumor necrosis inhibitor drugs; IL inhibitors - 17 - interleukin inhibitors- 17; IL inhibitors - 12/23 - interleukin inhibitors- 12/23; PsA - psoriatic arthritis; MTX - Methotrexate. Alternative medication may be considered: if a patient has TNF inhibitor contraindications, he/she should switch to IL inhibitor - 12/23, another IL inhibitor - 17 or add MTX; if a patient lacks response to IL inhibitor - 17 (initial response is positive, however, further treatment brings no improvement), he/she should switch to another IL inhibitor - 17; if a patient has a severe psoriasis, he/she should switch to another IL inhibitor - 17; if a patient shows a partial response to IL inhibitor - 17, he/she should add MTX; if a patient prefers a rarer drug administration, he/she should he/she should switch to IL inhibitor - 12/23. Alternative medication may be considered: if a patient lacks response to the current IL inhibitor - 17, he/she should switch to another IL inhibitor - 17; if a patient has a severe psoriasis, he/she should switch to another IL inhibitor - 17; if a patient shows a partial response to IL inhibitor - 17, he/she should add MTX. Alternative medication may be considered: if a patient has TNF inhibitor contraindications (congestive heart failure, previous severe and recurring infections, demyelinating disease), he/she should switch to IL inhibitor - 17 or add MTX; if a patient has a severe psoriasis which doesn't respond to therapy, he/she should switch to another IL inhibitor - 17 or add MTX. MTX may be added to the current therapy if there were no adequate response to the previously administered therapy.
acupuncture. Physical exercises with a reduced load (for instance, tai chi, yoga, swimming) and load-bearing exercises (for instance, running) should be restricted. Load-bearing exercises may be used instead of reduced-load exercises if the patients prefer them and do not have contraindications. Clinicians should urge patients to quit smoking using various methods as smoking cessation was proved to be very effective by a number of randomized trials [53, 54]. PsA patients who have an excess body weight or obesity should reduce their body weight to improve the potential pharmacological reaction.
Conclusions
This review focuses on the American College of Rheumatologists (ACR) Guidance of 2018 on Psori-atic arthritis treatment. Its aim is to help the healthcare providers to achieve optimum PsA management. PsA is a heterogeneous and multifaceted inflammatory disease with a multitude of clinical manifestations (peripheral arthritis, psoriasis, nail lesions, enthesitis, dactylitis, axial impairments) requiring a certain differential and incremental approach. Despite an increase in PsA's new therapies, their evidence-based efficacy is restricted. The Guidance will be edited with the new comparative study data being presented.
The ACR recognizes the patients' preferences and attitudes being the pivotal element of the Guidance. Decisions made at the patient group's meeting were submitted to vote at the peer committees to make sure that their viewpoint were included in the finalized version of the PsA Guidance. Among the feedback suggestions made by the patients they cite efficacy (for instance, to prevent further damage to the target organs, improve life quality, public involvement and functioning) and safety evaluation (for instance, to ensure low profile of side effects). Moreover, the patients discussed adverse treatment effects (for instance, fatigue, nausea, distemper) and their influence on life quality and public involvement drawing a conclusion that adverse event risks affected patients and healthcare providers' decision making. Treatment-to-target (T2T) was found to be a complicated concept for patients' understanding. Although they understood the value of improved results, they also thought that this strategy would increase their treatment and trip costs as they would have to travel more often to meet their doctors, also it would increase the negative treatment effects. Thus, making decision as to the treatment-to-target (T2T) option requires detailed discussions with patients, focusing your recommendations on their needs.
Potential aims of PsA treatment include determining minimal disease activity (MDA) and disease activity in psoriatic arthritis (DAPSA) [55, 56]. The Guidelines of ACR/NFP'2018 urge to treat an active PsA with TNF inhibitors (as a line of first defense) rather than with basic per os medication. The former are proved to prevent PsA's development and joint damage significantly. According to the European League
Against Rheumatism (EULAR)'s Recommendations on PsA [11, 57], its members do not agree upon basic per os medication being prescribed as a line of first defense. They emphasize upon the early and aggressive intervention in PsA patients as soon as the disease is diagnosed.
However, the above mentioned recommendations are provisional, and the expert group drew several possible exceptions. There are certain terms under which basic per os medication (Methotrexate (MTX), Sulfasalazine (SSZ), Cyclosporine, Leflunomide) are preferable to the biological agents: PsA's light or moderate severity: preference for the per os administration; concern over adverse biologic effects. TNF inhibitors are not the best option for patients with contraindications, including heart failure, previous severe infections or demyelinating diseases. In case of a concomitant inflammatory bowel disease (IBD), the group voted in favor of TNF inhibitor-a monoclonal antibodies or IL inhibitor — 12/23 rather than IL inhibitor — 17 or TNF inhibitor-a receptor (Etanercept). It was proved by the studies that TNF inhibitors and Ustekinumab (IL inhibitor — 12/23) are effective against IBD while Etanercept (TNF inhibitor-a receptor) and Secukinumab (IL inhibitor - 17) are not [49, 50].
At the same time, it was recognized that those recommendations do not take into account the whole PsA complexity, heterogeneity or the range of possible therapies (Glucocorticoids were not reviewed). Overall inconsistency in PsA's clinical features and development is caused by co-existence of several domains in one and the same patient and could not be designed as an algorithm. Moreover, efficacy evaluation and severity reports, discrepancies in the inclusion/exclusion criteria of PsA clinical trials complicate the comparison of therapeutic methods. Alternative therapy and its influence on significant outcomes, such as joint damage, were not explored. Recommendations as to inoculation of the patients while undergoing Tofacitinibum treatment were not included as they were not approved as PsA therapy.
As the National Psoriasis Foundation (NPF) and the American Academy of Dermatology (AAD) are both elaborating the isolated psoriasis treatment guidance, it's not included in the present review.
Conflicts of interests. Authors declare the absence of any conflicts of interests that might be construed to influence the results or interpretation of their manuscript.
Individual contributions by authors: Golovach Iryna.
Concept and design, literature review, writing and final editing; Yehudina Yelyzaveta. Literature review, writing and pre-press editing.
References
1. Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016 Jun;22(8 Suppl):s216-24.
2. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):545-68. doi: 10.1016/j.rdc.2015.07.001.
3. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9;376(10):957-970. doi: 10.1056/NEJMra1505557.
4. Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeco-nomics 2010;28(6):477-87. doi: 10.2165/11533010000000000-00000.
5. Singh JA, Strand V. Health care utilization in patients with spondyloarthropathies. Rheumatology (Oxford). 2009 Mar;48(3):272-6. doi: 10.1093/rheumatol-ogy/ken472.
6. Cresswell L, Chandran V, Farewell VT, Gladman DD. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 2011;70(2):305-8. doi: 10.1136/ard.2010.135087.
7. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73. doi: 10.1002/ art.21972.
8. Yaremenko OB, Fedkov DL, Yaremenko KM. The possibilities of objectification of inflammatory-destructive process in psoriatic arthritis. Ukrainian journal of rheumatology. 2011;46(4):1-7. (in Ukrainian).
9. Felson DT, Andersen JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727-35.
10. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-71. doi: 10.1002/art.39573.
11. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337.
12. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J DermatologTreat. 2004 Jan;15(1):27-9. doi: 10.1080/09541440042000269.
13. Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012 May;38(2):373-86. doi: 10.1016/j.rdc.2012.05.005.
14. Yaremenko OB, Fedkov DL. Efficacy and tolerance of psoriatic arthritis basic therapy using lefluno-mide. Ukrainian journal of rheumatology. 2011;(45):21-26.
15. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to metho-trexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 Apr;71(4):541-8. doi: 10.1136/ ard.2011.152223.
16. Heiberg MS, Kaufmann C, R0devand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, mul-ticentre study. Ann Rheum Dis. 2007 Aug;66(8):1038-42. doi: 10.1136/ard.2006.064808.
17. Eder L, Thavaneswaran A, Chandran V, Gladman DD. Tumour necrosis factor a
18. blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis. 2014 Jun;73(6):1007-11. doi: 10.1136/an-nrheumdis-2012-202959.
19. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RE-STORE1). Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.
20. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrex-ate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x.
21. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrex-ate in psoriatic arthritis. Rheumatology (Oxford) 2012;51(8):1368-77. doi: 10.1093/rheumatology/ kes001.
22. Gupta AK, Grober JS, Hamilton TA, et al. Sul-fasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995 May;22(5):894-8.
23. Combe B, Goupille P, Kuntz JL, Tebib J, Liote F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol. 1996 Jul;35(7):664-8.
24. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo- controlled study. Br J Rheumatol. 1990 Feb;29(1):46-9.
25. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89.
26. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related
and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis. 2007 Feb;66(2):163-8. doi: 10.1136/ ard.2006.057901.
27. Mease PJ, Kivitz AJ, Burch FX, et al. Etaner-cept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264-72. doi: 10.1002/art.20335.
28. Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 2010;37(6):1221-7. doi: 10.3899/jrheum.091093.
29. Mease PJ, Goffe BS, Metz J, Vander Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul;356(9227):385-90. doi: 10.1016/S0140-6736(00)02530-7.
30. Singh J A, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/ National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726.
31. Lubrano E, Scriffignano S, Perrotta FM. Abata-cept for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2018 Nov;14(11):899-905. doi: 10.1080/1744666X.2018.1527218.
32. Lubrano E, Perrotta FM. The role of LH-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2017;13(8):815-821. doi: 10.1080/1744666X.2017.1327354.
33. Gladman D, Rigby W, Azevedo VF, et al. To-facitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377(16):1525-1536. doi: 10.1056/NEJ-Moa1615977.
34. Metyas S, Tomassian C, Messiah R, Gettas T, Chen C, Quismorio A. Combination Therapy of Apre-milast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. Curr Rheumatol Rev. 2018. doi: 10.2174/1573397115666181130094455.
35. Krajewska-Wlodarczyk M, Owczarczyk-Sac-zonek A, Placek W, Wojtkiewicz M, Wojtkiewicz J. Effect of Methotrexate in the Treatment of Distal In-terphalangeal Joint Extensor Tendon Enthesopathy in Patients with Nail Psoriasis. J Clin Med. 2018;7(12). pii: E546. doi: 10.3390/jcm7120546.
36. D'Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017 Mar 2;9:21-28. doi: 10.2147/ 0ARRR.S56073.
37. Yun H, Xie F, Delzell E, et al. Comparative Risk of Hospitalized Infection Associated With Biologic
Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Arthritis Rheumatol. 2016 Jan;68(1):56-66. doi: 10.1002/art.39399.
38. BerekmeriA, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719-730. doi: 10.1080/1744666X.2018.1512404.
39. Elmamoun M, Chandran V. Role of Methotrexate in the Management of Psoriatic Arthritis. Drugs. 2018;78(6):611-619. doi: 10.1007/s40265-018-0898-2.
40. Favalli EG, Selmi C, Becciolini A, et al. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. Arthritis Care Res (Hoboken). 2017 Jun;69(6):867-874. doi: 10.1002/acr.23090.
41. Ritchlin CT, Krueger JG. New Therapies for Psoriasis and Psoriatic Arthritis. Curr Opin Rheumatol. 2016;28(3):204-210. doi: 10.1097/ BOR.0000000000000274.
42. Boutet MA, Nerviani A, Afflitto GG, Pitzalis C. Role of the Ln-23/I.n-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018 Feb 9;19(2). pii: E530. doi: 10.3390/ijms19020530.
43. Wang EA, Suzuki E, Maverakis E, Adamop-oulos IE. Targeting 1.-17 in psoriatic arthritis. Eur J Rheumatol. 2017 Dec;4(4):272-277. doi: 10.5152/eur-jrheum.2017.17037.
44. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-I.H-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73(6):990-9. doi: 10.1136/ annrheumdis-2013-204655.
45. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282-98. doi: 10.1002/art.39298.
46. Janssen Research Development, LLC, sponsor. An efficacy and safety study of ustekinumab in participants with active nonradiographic axial spondyloarthri-tis. ClinicalTrials.gov Identifier: NCT02407223. 2017. Available from: https://clinicaltrials.gov/ct2/show/ NCT02407223. Accessed: October 25, 2017.
47. Janssen Research Development, LLC, sponsor. A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFa Naive Participants With Active Radiographic Axial Spondylo-
arthritis. ClinicalTrials.gov Identifier: NCT02437162. 2018. Available from: https://clinicaltrials.gov/ct2/ show/NCT02437162. Accessed: October 29, 2018.
48. Janssen Research & Development, LLC, sponsor. A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis. ClinicalTrials.gov identifier: NCT02438787. 2018. Available from: https://clinical-trials.gov/ct2/show/NCT02438787. Accessed: October 10, 2018.
49. Sakkas LI, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013 Dec;43(3):325-34. doi: 10.1016/j.semar-thrit.2013.04.005.
50. Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017 Jun 19;357:j2505. doi: 10.1136/bmj.j2505.
51. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668.
52. Maybury CM, Jabbar-Lopez ZK, Wong T, Dhil-lon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol 2014;171(1):17-29. doi: 10.1111/bjd.12941.
53. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51(4):778ß86. doi: 10.1016/j. jhep.2009.06.008.
54. Golovach IYu. The Role of Smoking in the Development of Psoriatic Arthritis and Psoriasis. Bol', sustavy, pozvonocnik. 2016;(23):42-48. doi: 10.22141/2224-1507.3.23.2016.85006. (in Russian).
55. Taylor G, McNeill A, Girling A, Farley A, Lind-son-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014 Feb 13;348:g1151. doi: 10.1136/ bmj.g1151.
56. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69(1):48-53. doi: 10.1136/ard.2008.102053.
57. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75(5):811-8. doi: 10.1136/an-nrheumdis-2015-207507.
58. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-71. doi: 10.1002/art.39573.
Received 07.01.2019 ■
Головач 1.Ю.1, £гуд'ша €.Д.2
1Кл'ш'мналкарня «Феофаня»Державногоуправлння справами,м. КиУв, УкраУна 2ДЗ «Дн'тропетровська державна медична академ'я» МОЗ УкраУни, м. Дн'тро, УкраУна
Сучаснг рекомендацм щодо лгкування псоргатичного артриту згiдно з рекомендацгями Американського коледжу ревматологiв i НацгональноТ органiзацГí з псорiазУ 2018 року
Резюме. Псорiатичний артрит (ПсА) — це хрошчне за-пальне скелетно-м'язове захворювання, асоцiйоване з ncopia30M, яке манiфестуe зазвичай з периферичного артриту, дактилиу, ентезиту та/чи спондилиу. Рання щен-тифiкацiя та дiагностика ПсА, раннiй початок терапи важ-ливi для покращення довгострокових наслiдкiв хвороби. Клiнiчна картина ПсА е гетерогенною, i лiкарi досить часто стикаються з проблемами при визначенш стратегiй ль кування. Метою нашого огляду були надання й штерпре-тацiя рекомендацiй Американського коледжу ревмато-логiв (ACR) i Нацiональноi органiзацii з псорiазу (NFP) 2018 року з лшування активного ПсА у дорослих з вико-ристанням фармакологiчних i нефармакологiчних мето-дiв. Цi рекомендаци щодо лшування ПсА можуть допо-могти як клшщистам, так i пацiентам досягти оптималь-них рiшень щодо менеджменту хвороби. У рекомендац1ях наведенi стратеги вибору препаратiв для лiкування активного ПсА при рiзних клшчних ситуац1ях та залежно вщ
проведено! попередньо! терапи. Наявнiсть або вщсутшсть коморбщних станiв, таких як запальне захворювання кишечника, увит, дiабет або серйознi iнфекцii, а також зна-ння попередн1х методiв лшування е факторами, що дозво-ляють зробити вибiр оптимально! терапи для окремого па-цiента в даний момент часу, застосовуючи iндивiдуальний пщхщ. Рекомендаци ACR/NFP щодо лiкування активного ПсА рекомендують iнгiбiтори фактора некрозу пухлини, а не пероральнi низькомолекулярш препарати як препара-ти першо! лiнii, саме цi бiологiчнi агенти запобтають про-гресуванню захворювання та пошкодженню суглобiв. На-голошуеться на необидносл ранньо! та агресивно! терапи у пащенпв з вперше виявленим ПсА. Ключовi слова: псорiатичний артрит; псорiаз; активнiсть процесу; рекомендаци; лжування; менеджмент; шпбгго-ри фактора некрозу пухлини; шпбггори iнтерлейкiну-17; iнгiбiтори штерлейышв-12/23; метотрексат; лiкування до досягнення мети
Головач И.Ю.1, Егудина Е.Д.2
1Клиническая больница «Феофания» Государственного управления делами, г. Киев, Украина 2ГУ «Днепропетровская медицинская академия» МЗ Украины, г. Днепр, Украина
Современные рекомендации по лечению псориатического артрита согласно рекомендациям Американского колледжа ревматологов и Национальной
организации псориаза 2018 года
Резюме. Псориатический артрит (ПсА) — это хроническое воспалительное скелетно-мышечное заболевание, ассоциированное с псориазом, которое манифестирует обычно как периферический артрит, дактилит, энтезит и/или спондилит. Ранняя идентификация и диагностика ПсА, раннее начало терапии важны для улучшения долгосрочных исходов болезни. Клиническая картина ПсА является неоднородной, и врачи довольно часто сталкиваются с проблемами при определении стратегий лечения. Целью нашего обзора были представление и интерпретация рекомендаций Американского колледжа ревматологов (ACR) и Национальной организации псориаза (NFP) 2018 года по лечению активного ПсА у взрослых с использованием фармакологических и нефармакологических методов. Эти рекомендации по лечению ПсА могут помочь как клиницистам, так и пациентам достичь оптимальных решений по менеджменту болезни. В рекомендациях представлены стратегии выбора препаратов для лечения активного ПсА при различных клинических ситуациях и в за-
висимости от проводимой предыдущей терапии. Наличие или отсутствие коморбидных состояний, таких как воспалительное заболевание кишечника, увеит, диабет или серьезные инфекции, а также знания предыдущих методов лечения являются факторами, которые позволяют сделать выбор оптимальной терапии для отдельного пациента в данный момент времени, используя индивидуальный подход. Рекомендации ACR/NFP по лечению активного ПсА рекомендуют ингибиторы фактора некроза опухоли, а не пероральные низкомолекулярные препараты как препараты первой линии, именно эти биологические агенты предупреждают прогрессирование заболевания и повреждение суставов. Отмечается необходимость ранней и агрессивной терапии у пациентов с впервые выявленным ПсА. Ключевые слова: псориатический артрит; псориаз; активность процесса; рекомендации; лечение; менеджмент; ингибиторы фактора некроза опухоли; ингибиторы ин-терлейкина-17; ингибиторы интерлейкинов-12/23; мето-трексат; лечение до достижения цели
